Replimune Group Inc at JPMorgan Healthcare Conference Transcript
Okay. Let's get started. Welcome to the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan.
I am joined by my team, Priyanka Grover and Malcolm Kuno. Our next presenting company is Replimune, and presenting on behalf of the company, we have the CEO. Philip?
Thanks, Anupam. Replimune. Replimune is the industry leader in tumor-directed oncolytic immunotherapy. We have 3 wholly owned programs, RP1, 2 and 3. RP1 data to date supports the emergence of a major skin cancer franchise.
We have 2 registrational studies ongoing. The first is in frontline cutaneous squamous cell carcinoma, where in a prior single-arm study, we showed a very impressive almost 1 in 2 complete response rate.
We have subsequently fully enrolled a 211-patient randomized controlled study of RP1 plus cemiplimab standard of care against
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
